A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

PHASE2CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Rheumatoid Arthritis
Interventions
DRUG

CP-690,550

Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).

DRUG

placebo

Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects

Trial Locations (57)

12206

Pfizer Investigational Site, Albany

13905

Pfizer Investigational Site, Binghamton

14618

Pfizer Investigational Site, Rochester

14760

Pfizer Investigational Site, Olean

16635

Pfizer Investigational Site, Duncansville

18015

Pfizer Investigational Site, Bethlehem

19610

Pfizer Investigational Site, Wyomissing

21502

Pfizer Investigational Site, Cumberland

26301

Pfizer Investigational Site, Clarksburg

27804

Pfizer Investigational Site, Rocky Mount

28210

Pfizer Investigational Site, Charlotte

29601

Pfizer Investigational Site, Greenville

32216

Pfizer Investigational Site, Jacksonville

33542

Pfizer Investigational Site, Zephyrhills

33613

Pfizer Investigational Site, Tampa

34102

Pfizer Investigational Site, Naples

34652

Pfizer Investigational Site, New Port Richey

34668

Pfizer Investigational Site, Port Richey

37909

Pfizer Investigational Site, Knoxville

40504

Pfizer Investigational Site, Lexington

45417

Pfizer Investigational Site, Dayton

48025

Pfizer Investigational Site, Bingham Farms

55435

Pfizer Investigational Site, Edina

58701

Pfizer Investigational Site, Minot

60053

Pfizer Investigational Site, Morton Grove

60061

Pfizer Investigational Site, Vernon Hills

61107

Pfizer Investigational Site, Rockford

65203

Pfizer Investigational Site, Columbia

65212

Pfizer Investigational Site, Columbia

67208

Pfizer Investigational Site, Wichita

72401

Pfizer Investigational Site, Jonesboro

73112

Pfizer Investigational Site, Oklahoma City

75150

Pfizer Investigational Site, Mesquite

75231

Pfizer Investigational Site, Dallas

78705

Pfizer Investigational Site, Austin

80304

Pfizer Investigational Site, Boulder

85234

Pfizer Investigational Site, Gilbert

85253

Pfizer Investigational Site, Paradise Valley

90095

Pfizer Investigational Site, Los Angeles

91786

Pfizer Investigational Site, Upland

95628

Pfizer Investigational Site, Fair Oaks

95661

Pfizer Investigational Site, Roseville

98104

Pfizer Investigational Site, Seattle

98122

Pfizer Investigational Site, Seattle

98405

Pfizer Investigational Site, Tacoma

98664

Pfizer Investigational Site, Vancouver

06611

Pfizer Investigational Site, Trumbull

01453

Pfizer Investigational Site, Leominster

01605

Pfizer Investigational Site, Worcester

01608

Pfizer Investigational Site, Worcester

03756

Pfizer Investigational Site, Lebanon

43-400

Pfizer Investigational Site, Cieszyn

64-000

Pfizer Investigational Site, Kościan

60-773

Pfizer Investigational Site, Poznan

87-100

Pfizer Investigational Site, Torun

02-256

Pfizer Investigational Site, Warsaw

50-088

Pfizer Investigational Site, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01359150 - A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo | Biotech Hunter | Biotech Hunter